Naqi Logix Launches Earbud–Based Human Machine Interface Research with the Institute for Advanced Consciousness Studies

Naqi Logix Logo

Two-phase bio signal study, beginning July 2026, will benchmark Naqi’s neural earbud against laboratory-standard EEG across a spectrum of cognitive states.

VANCOUVER, BC, CANADA, July 21, 2026 /EINPresswire.com/ -- Naqi Logix Inc. (“Naqi” or the “Company”), an AI-Neurotechnology Company that is the silent, invisible interface between humans and technology, and the Institute for Advanced Consciousness Studies (“IACS”), a Santa Monica–based 501(c)(3) research institute, announces a sponsored research collaboration to detect, characterize, and validate EEG and related biosignals captured by Naqi’s neural earbud platform.

"Independent scientific validation is an important milestone for Naqi," said Mark Godsy, CEO of Naqi Logix. "Partnering with one of the foremost institutes focused on neural research underscores both the potential of our technology and our commitment to advancing the science behind non-invasive neural interfaces. I couldn't be more excited to support this collaboration and the important discoveries it may enable."

The collaboration will be led by Dr. Nicco Reggente, Research Director of IACS, Co-Principal Investigator for the IACS, and Dr. Rodney Sappington, Head of AI at Naqi Logix, Co-Principal Investigator for the Company. The work brings together IACS’s expertise in high-density EEG, fMRI, and neural correlates of consciousness with Naqi’s patented software platform, which translates subtle facial micro-gestures into digital commands, enabling hands-free, voice-free, screen-free and camera-free control of computers, simulators, robotics, and other connected devices.

First, researchers will characterize the neural and physiological signals captured by Naqi's non-invasive earbud platform. Second, the technology will undergo independent validation against established laboratory EEG methods to evaluate performance across multiple cognitive tasks. The findings are expected to be documented in technical papers and submitted for peer-reviewed publication.

Statements from the Investigators

“Naqi’s earbud sits at a frontier where consumer form factor meets serious neuroscience,” said Dr. Reggente. “Our job at IACS is to apply the same rigor we bring to fMRI and high-density EEG research to an everyday wearable, and to publish what we find, whatever the result. That’s how this technology earns its place in clinical, accessibility, and consumer contexts.”

“Collaborating with IACS allows us to benchmark Naqi’s signals against the gold standard of laboratory neuroscience,” said Dr. Sappington. “For a platform that aspires to be the universal interface between people and devices, scientific validation isn’t optional. This study is foundational to the next generation of Naqi features.”

About the Institute for Advanced Consciousness Studies
IACS is a 501(c)(3) non-profit research institute in Santa Monica, California, applying high-density EEG, fMRI, DTI, transcranial focused ultrasound, and machine learning to the study of consciousness and human flourishing. More at advancedconsciousness.org

About Naqi Logix
Naqi Logix Inc. is an AI-Neurotechnology Company that is the silent, invisible interface between humans and technology. Naqi's non-invasive, earbud-based neural interface platform captures biosignals and uses proprietary AI to interpret intent, turning subtle facial micro-gestures and head movements into real-time digital commands. Safe, private, and camera-free, Naqi enables hands-free, voice-free, screen-free, implant-free control across computers, mobile devices, robotics, and connected environments. www.naqilogix.com.

Learn more on how to invest.*

Investor Information
* Accredited investors are not limited in the amounts they may invest. Non-accredited investors may invest no more than 10% of the greater of annual income or net worth (for individuals) or 10% of the greater of annual revenue or net assets at a fiscal year-end (for entities). This Reg A+ Offering is made available through Dealmaker Securities LLC, member FINRA / SIPC . This investment is speculative, illiquid, and involves risk, including the possible loss of your entire investment. Past performance is not indicative of future results. In addition, as described in the Offering Circular, the Company retains the right to continue the Offering beyond the Termination Date, in its sole discretion. Details of the Offering, including the Offering Circular filed with the U.S. Securities and Exchange Commission.

Investor Relations
David Rokoss
Investor@naqilogix.com
1-888-627-4564 ext.1

Media Contact
Jami Lah
Marketing Director
outreach@naqilogix.com
1-888-627-4564

Forward Looking Statements

This press release, including any materials referenced herein, may contain forward-looking information or statements under applicable Canadian and U.S. securities laws (collectively, “forward-looking statements”), including, without limitation, statements regarding [the future plans, objectives and goals of Naqi Logix Inc. (the “Company”); the Company’s future financial results; the anticipated advancement of and benefits derived from the Company’s neurotechnology program; the results of ongoing equity and debt financing activities and the Company’s agreement with IACS. Forward-looking statements may be identified by terminology such as “believes,” “expects,” “anticipates,” “estimates,” “intends,” “plans,” “projects,” “potential,” “may,” “might,” “will,” “could,” “should,” or “would,” or negative versions thereof or similar expressions.

Forward-looking statements reflect current beliefs of management of the Company and are based on certain factors and assumptions, which by their nature are subject to inherent risks, uncertainties and assumptions about the Company, including, among others, related to the Company’s business developments and growth strategy; the Company’s future performance, business prospects and opportunities; the Company’s limited operating history and history of losses; the availability of adequate financing and on favorable terms; the Company’s foreign private issuer status; customer demand for the Company’s products and services; technological changes; the competitive landscape; the Company’s ability to manufacture or distribute products and services; the protection of the Company’s intellectual property and user data; legal, tax and regulatory complexity and uncertainty including with respect to required regulatory approvals for the Company’s technologies for medical applications; internal controls; the Company’s ability to attract and retain skilled personnel; uncertain political and economic conditions; inflation and interest rate variability; supply chain and engineering challenges; cybersecurity threats; the Company’s success at managing risks; and other risks discussed in the Company’s periodic and current reports and offering statements filed with the U.S. Securities and Exchange Commission, which are available for review at www.sec.gov. Forward-looking statements are not guarantees of future performance and actual events and results could differ materially from those expressed or implied by forward-looking statements.

Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date of the press release or as of the date otherwise specifically indicated herein. Other than as specifically required by applicable law, the Company does not intend to update any forward-looking statements whether as a result of new information, future events or otherwise.

Jami Lah
Naqi Logix Inc
email us here

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.